

TOPIC OF THE ISSUE: REVIEW ARTICLE

Year : 2011 | Volume : 59 | Issue : 2 | Page : 229--235

O⁶-methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: A review of current status

Vaishali Suri, Prerana Jha, Mehar Chand Sharma, Chitra Sarkar

Department of Pathology, All India Institute of Medical Sciences (AIIMS), New Delhi, India

Correspondence Address:

Chitra Sarkar

Department of Pathology, AIIMS, New Delhi - 110029
India

Assessment of promoter methylation of the O⁶-methylguanine DNA methyltransferase (MGMT) gene has recently gained importance in molecular profiling of high-grade gliomas. It has emerged not only as an important prognostic marker but also as a predictive marker for response to temozolomide in patients with newly diagnosed glioblastoma. Further, recent studies indicate that MGMT promoter methylation has strong prognostic relevance even in anaplastic (grade III) gliomas, irrespective of therapy (chemotherapy or radiotherapy). This article provides an overview of its use as a predictive and prognostic biomarker, as well as the methods employed for its assessment and use in therapeutic decision making.

How to cite this article:

Suri V, Jha P, Sharma MC, Sarkar C. O⁶-methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: A review of current status. *Neurol India* 2011;59:229-235

How to cite this URL:

Suri V, Jha P, Sharma MC, Sarkar C. O⁶-methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: A review of current status. *Neurol India* [serial online] 2011 [cited 2011 Apr 9];59:229-235

Available from: <http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2011;volume=59;issue=2;spage=229;epage=235;aulast=Suri;type=0>

Saturday, April 09, 2011

[Site Map](#) | [Home](#) | [Contact Us](#) | [Feedback](#) | [Copyright and Disclaimer](#)